Astrazeneca PLC (AZN) Receives News Impact Score of 0.23
Media headlines about Astrazeneca PLC (NYSE:AZN) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Astrazeneca PLC earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.9612036014607 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Zacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per Share (americanbankingnews.com)
- Critical Contrast: Astrazeneca PLC (AZN) versus Its Peers (americanbankingnews.com)
- Astrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital Markets (americanbankingnews.com)
- AstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics (rttnews.com)
- Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist (finance.yahoo.com)
Shares of Astrazeneca PLC (AZN) traded down $0.04 during midday trading on Monday, reaching $33.43. 1,333,403 shares of the company’s stock traded hands, compared to its average volume of 4,805,815. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a market cap of $83,090.00, a price-to-earnings ratio of 7.99, a PEG ratio of 3.16 and a beta of 0.79.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.32 EPS. research analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.
A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets set a $38.00 price objective on shares of Astrazeneca PLC and gave the stock a “buy” rating in a report on Wednesday, November 15th. Leerink Swann boosted their price objective on shares of Astrazeneca PLC from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Citigroup Inc. upgraded shares of Astrazeneca PLC to a “buy” rating in a report on Wednesday, October 18th. Cowen and Company restated a “hold” rating and issued a $37.00 price objective on shares of Astrazeneca PLC in a report on Tuesday, October 17th. Finally, Credit Suisse Group upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus price target of $34.20.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.